Return Stacked Bonds & Managed Futures ETF Cboe Validus S&P 500 Dynamic PutWrite Index ETF (BATS: PUTD)

Latest news for Return Stacked Bonds & Managed Futures ETF Cboe Validus S&P 500 Dynamic PutWrite Index ETF (BATS:PUTD)

The Index employs a rules-driven approach, without the use of leverage, with the goal of identifying a portfolio of written put options on the S&P 500 Index, that when sold in accordance with the Indexs rules driven approach, will collectively provide over the long term a total return that will exceed that of the S&P 500 Index with lower volatility and drawdown. That is, the Fund is designed to be a less risky investment, with fewer and smaller drops in value than the S&P 500 Index. 

First American Government Obligations Fund

Cboe Validus S&P 500 Dynamic PutWrite Index ETF

Return Stacked Bonds & Managed Futures ETF Cboe Validus S&P 500 Dynamic PutWrite Index ETF

WIIM

GTES

Gates Industrial shares are trading higher after it was announced the stock will join the S&P SmallCap 600.

Bloom Energy shares are trading higher after the company announced a strategic partnership with CoreWeave.

News

Danaher Announced The Launch Of Two New Clinical Laboratory Improvement Amendments And College Of American Pathologists-certified Labs Intended To Accelerate The Development Of Companion Diagnostics And Complementary Diagnostics

GFAI

Guardforce Announced That Its Wholly Owned Subsidiary In Mainland China Has Significantly Expanded Its Contracts With Two Renowned Retail Clients, Each Having Worked With Beijing Wanjia For Over 10 Years

Guidance

LILM

Lilium Confirmed Its Delivery Schedule Allowing First Customer Deliveries In 2026, with First Manned Flight Now Scheduled For Early 2025

AMAT

AMKR

AVGO

KLAC

LRCX

MRVL

NVDA

Shares of semiconductor stocks are trading lower following soft guidance from ASML.

Piper Sandler analyst Ryan Todd maintains BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) with a Neutral and lowers the price target from $43 to $40.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on BP, Lowers Price Target to $40

JMP Securities analyst Matthew Carletti maintains ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) with a Market Outperform and lowers the price target from $22 to $20.

JMP Securities Maintains Market Outperform on ProAssurance, Lowers Price Target to $20

Omnicom Group shares are trading lower. The company reported Q2 financial results.

JBHT

J.B. Hunt Transport Services shares are trading lower after the company reported worse-than-expected Q2 financial results.

GAUZ

Gauzy Announced The Implementation Of Its Cutting-edge 'smart-vision' Camera Monitoring System On A Portion Of The City Of Paris's Buses, Beginning With The 2024 Olympics

DDOG

Datadog shares are trading lower following a report suggesting that the company is considering buying GitLab.

JMP Securities analyst Jordan Bender maintains MGM Resorts Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Market Outperform and raises the price target from $58 to $59.

JMP Securities Maintains Market Outperform on MGM Resorts Intl, Raises Price Target to $59

Offerings

Wag! Group Announced The Pricing Of Its Underwritten Public Offering Of 7,407,407 Shares Of Its Common Stock At A Price To The Public Of $1.35 Per Share

Piper Sandler analyst Brandan Nosal maintains Mercantile Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBWM#NASDAQ">MBWM</a>) with a Neutral and raises the price target from $42 to $53.

MBWM

Piper Sandler Maintains Neutral on Mercantile Bank, Raises Price Target to $53

Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.64 by 51.56 percent. The company reported quarterly sales of $2.042 billion which beat the analyst consensus estimate of $2.030 billion by 0.59 percent. This is a 1.16 percent decrease over sales of $2.066 billion the same period last year.

Earnings

Earnings Beats

ALLY

Ally Financial Q2 2024 Adj EPS $0.97 Beats $0.64 Estimate, Adj. Revenue $2.042B Beat $2.030B Estimate

Citizens Financial Group shares are trading lower. The company reported Q2 EPS results.

Worldcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WLD</a>) has experienced a <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39426148/sam-altman-founded-worldcoin-outstrips-gains-of-bitcoin-ethereum-after-major-relief-from-k">substantial 40% price increase</a> following an announcement by Tools for Humanity (TFH) regarding an extension of token lockup periods for early contributors.
What Happened: This news has sparked renewed interest in <a href="https://www.benzinga.com/money/how-to-buy-worldcoin">Worldcoin</a>, which aims to create a global identity and financial network.
According to a recent blog <a href="https://worldcoin.org/blog/announcements/extended-lock-up-for-tfh-team-and-investors">post </a>by the Worldcoin Foundation, TFH has informed them that the unlock schedule for 80% of the WLD tokens held by TFH&#8217;s team members and investors will be extended from 3 to 5 years. 
This decision aligns with the long-term vision of the Worldcoin project and has been well-received by the market.
The original unlock schedule was set to begin on July 24, 2024, with tokens becoming available daily in a linear fashion over two years. 
Under the new plan, while the first year remains unchanged, the subsequent unlocking will occur more gradually over four years, concluding by the end of July 2028.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39652442/multicoin-capital-announces-1m-match-for-pro-crypto-senate-candidates-in-solana-donations">Multicoin Capital Announces $1M Match For Pro-Crypto Senate Candidates In Solana Donations</a>
Why It Matters: This extension is expected to have a significant impact on WLD&#8217;s circulating supply.
The daily unlock rate will decrease from approximately 3.3 million WLD to 2 million WLD, effectively slowing the rate at which new tokens enter the market by about 40%.
It&#8217;s important to note that this change does not affect WLD grants for verified World ID holders, which constitute the majority of tokens in circulation. 
As of the announcement, more than 211 million WLD have been claimed by World ID holders, representing over 77% of the 275 million WLD currently circulating.
The Worldcoin project, which boasts more than 6 million unique humans participating in its network, continues to focus on its mission of becoming the world&#8217;s largest identity and financial network. 
The project emphasizes the importance of proving human uniqueness in an era of <a href="https://www.benzinga.com/money/tips-how-to-use-ai-for-crypto-trading">increasing AI influence</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39651051/these-altcoins-show-bullish-signals-while-bitcoin-faces-critical-juncture">These Altcoins Show Bullish Signals While Bitcoin Faces Critical Juncture</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$WLD

Sam Altman's AI-Themed 'Ethereum Killer' Worldcoin Surges 40%: What's Going On?

ASLN

ASLAN Pharmaceuticals Announced That Its Sole Operating Subsidiary Has Filed For Voluntary Liquidation And All Employees At ASLAN SG And Fellow Subsidiary ASLAN Pharmaceuticals Have Been Terminated Effective Immediately

Wednesday, Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39808248/genentech-announces-positive-phase-i-results-of-its-oral-glp-1-receptor-agonist-ct-996-for-the-tre" rel="noreferrer noopener">type 2 diabetes and obesity</a>.
CT-996 is an investigational, once-daily oral small molecule GLP-1 receptor agonist being developed for type 2 diabetes and obesity.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39645630/roches-new-immunotherapy-fails-to-show-benefit-over-mercks-blockbuster-keytruda-in-lung-cancer-pa" rel="noreferrer noopener">Roche&#8217;s New Immunotherapy Fails To Show Benefit Over Merck&#8217;s Blockbuster Keytruda In Lung Cancer Patients</a>.
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
Roche added CT-996 when it acquired Carmot Therapeutics for $2.7 billion in cash. Additionally, Carmot&#8217;s equity holders are entitled to receive payments of up to&nbsp;$400 million&nbsp;depending on&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36064233/roche-joins-bandwagon-to-challenge-novo-nordisk-eli-lilly-for-weight-loss-drugs" rel="noreferrer noopener">achieving certain milestones</a>.&nbsp;
More than four billion people &#8211; about 50% of the world&#8217;s population &#8211; are estimated to be impacted by obesity or will be overweight by 2035.
CT-996 was well tolerated, with mostly mild or moderate gastrointestinal-related adverse events, consistent with the safety profile of the incretin drug class.
There were no treatment discontinuations related to the study drug.
The study results also showed that blood levels of CT-996 were largely unaffected either during fasting or after a standardized high-fat meal.
Thus, CT-996 could potentially be dosed without regard to meal timing, thereby affording greater dosing flexibility for patients.
Based on the study data, CT-996 is anticipated to be used as a therapy for achieving glycaemic control and inducing weight loss and potentially for oral weight maintenance therapy following weight loss induced by injectables.
Price Action: RHHBY shares closed at $36.27 on Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/05/38878582/roche-to-ride-booming-obesity-treatment-market-with-newly-acquired-drug-candidate" target="_blank" rel="noreferrer noopener">Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate</a>.</li>
</ul>

Biotech

Equities

Large Cap

Health Care

General

RHHBY

Roche Highlights Encouraging Data From Newly-Acquired Second Weight Loss Drug Candidate In Early-Stage Study

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Return Stacked Bonds & Managed Futures ETF Cboe Validus S&P 500 Dynamic PutWrite Index ETF

News

Latest news for Return Stacked Bonds & Managed Futures ETF Cboe Validus S&P 500 Dynamic PutWrite Index ETF (BATS:PUTD)